Allakos started at buy at BofA Securities

1 BUSINESS

Business News - Opportunities - Reviews

 

 

Allakos Inc.

Allakos, Inc. engages in the development of therapeutic antibodies. Its primary product is AK002, a monoclonal antibody used for the treatment of various eosinophil and mast cell related diseases such as eosinophilic gastritis, urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis. The company was founded by Christopher Bebbington, Nenad Tomasevic, Bruce S. Bochner, and Robert Schleimer in 2012 and is headquartered in Redwood City, CA.

1 BUSINESS

Business News - Opportunities - Reviews

 

 

Leave a Reply